VMY-1-103 - CAS 1209002-43-6

VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G (2) /M. VMY-1-103 increased the sub G (1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma.

Others, Apoptosis, Caspase

Others, Proteases/Proteasome, Apoptosis

1208953

C34H42ClN9O4S

708.27

N(C1=C2C(N(C(C)C)C=N2)=NC(N[C@H](C(C)C)CO)=N1)C3=CC(Cl)=C(C(NCCNS(=O)(=O)C=4C5=C(C(N(C)C)=CC=C5)C=CC4)=O)C=C3

-20°C

Ice Packs

Small Compound